Form 4: Atara Biotherapeutics Director Equity Grant

Director William K. Heiden received a grant of 12,000 restricted stock units from Atara Biotherapeutics.

Summary

• Director William K. Heiden was granted 12,000 restricted stock units (RSUs) on June 9, 2026.
• The grant was issued at a price of $0 per share.
• Following this transaction, the director's total beneficial ownership of common stock increased to 34,188 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• The issuance of equity results in minor dilution to existing shareholders.

Risks

• Vesting is subject to the director's continuous service to the company.

Future Outlook

The RSUs are scheduled to vest on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The grant structure is consistent with standard director compensation packages for mid-cap and small-cap biotech firms.
• Vesting schedules tied to annual meetings are common practice for board members in the industry.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of the 12,000 RSUs on June 9, 2027, or the next annual meeting.

Key Dates

Keywords

Atara Biotherapeutics, ATRA, Form 4, Insider Transaction, Equity Grant, Director Compensation